User:Adam Davis/Sandbox 1: Difference between revisions

From Proteopedia
Jump to navigationJump to search
No edit summary
No edit summary
Line 21: Line 21:
== Disease ==
== Disease ==


PPARδ agonists are being investigated as treatments for a number of metabolic disorders including dyslipidemia, Type 2 Diabetes, and cardiovascular disease. Though there are some health benefits associates with PPARα and γ agonists, these drugs also have undesirable side effects including such as edema and weight gain for PPARα, and carcinogenicity for PPARγ<ref>DOI 10.1038/35013000</ref>. If PPARδ agonists are to be used clinically, it is thus important to develop a ligand that does not also bind to the other PPARs.  
PPARδ agonists are being investigated as treatments for a number of metabolic disorders, but have not yet been deployed clinically. Though there are some health benefits associates with PPARα and γ agonists, these drugs also have undesirable side effects including such as edema and weight gain for PPARα, and carcinogenicity for PPARγ<ref>DOI 10.1038/35013000</ref>. If PPARδ agonists are to be used clinically, it is thus important to develop a ligand that does not also bind to the other PPARs.  


== Relevance ==
== Relevance ==

Revision as of 12:41, 29 April 2025

PPARδ Bound to GW074

Peroxisome proliferator activated receptors (PPARs) are ligand-activated transcription factors that regulate metabolism of lipids and glucose. They are divided into three families: α, γ, and δ. Activation of PPARδ by endogenous ligands results in increased insulin sensitivity. (Note: In the literature, PPARδ is sometimes also called PPARβ). Synthetic PPARδ agonists hold significant promise for treatment of metabolic and cardiovascular diseases.

PDB ID: 3TKM

Drag the structure with the mouse to rotate

References

Proteopedia Page Contributors and Editors (what is this?)

Adam Davis